EANM 2025: 225Ac-SSO110 Data Supports the Advancement for ES-SCLC and MCC
“These oral presentations demonstrate Ariceum’s commitment to leading innovation in targeted radiotherapeutics,” said Germo Gericke, MD, Chief Medical Officer of Ariceum Therapeutics. “For the first time, we are presenting data showing minimal in-vivo redistribution of daughter radionuclides with 225Ac-SSO110, a non-internalizing SSTR2 antagonist, an important advance in our understanding of targeted alpha therapy. In parallel, our SANTANA-225 study showcases an innovative, first‑in-class approach for patients with ES‑SCLC and MCC. With the SANTANA-225 initial safety readout expected in 2026 and preliminary efficacy in 2027, we remain committed to setting new standards in both research and patient care for diseases with high unmet needs.”
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month